Psychostimulant augmentation of second generation antidepressants: A case series

Masand, Prakash S.; Anand, Vishal; Tanquary, John F.

doi:10.1002/(sici)1520-6394(1998)7:2<89::aid-da8>3.0.co;2-0

Cited by 48 publications

(11 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are several positive open trials, audits and case reports regarding the use of psychostimulants to augment standard antidepressant treatment, including tricyclic antidepressants (Gwirtsman 1994), monoamine oxidase inhibitors (Feinberg 2004), selective serotonin reuptake inhibitors (Ninan 2004), venlafaxine (Masand 1998) and mirtazapine (Schillerstrom 2002).…”

Section: Adjunctive Treatmentmentioning

confidence: 87%

Beyond ADHD and narcolepsy: psychostimulants in general psychiatry

Ng¹,

O'Brien²

2009

Adv. psychiatr. treat

View full text Add to dashboard Cite

SummaryPsychostimulants (dexamphetamine, methylphenidate, modafinil) reduce fatigue, promote alertness and wakefulness, and have possible mood-enhancing properties. In modern psychiatric practice, their use has been limited to attention-deficit hyperactivity disorder and sleep disorders such as narcolepsy. Despite this, research has continued into psychostimulant use in general psychiatry, especially in the treatment of depression and fatigue. This article reviews the recent literature regarding psychostimulant use in general and consultation-liaison psychiatry. Although psychostimulants continue to attract clinical research, there is currently not enough evidence to recommend their routine use for general psychiatric conditions.

show abstract

Section: Adjunctive Treatmentmentioning

confidence: 87%

Beyond ADHD and narcolepsy: psychostimulants in general psychiatry

Ng¹,

O'Brien²

2009

Adv. psychiatr. treat

View full text Add to dashboard Cite

show abstract

“…The dopamine and norepinephrine reuptake inhibitor bupropion was developed in the 1980’s as an antidepressant [53], and it has since been repeatedly shown to boost the therapeutic response to norepinephrinergic and/or serotonergic antidepressants (and decrease sexual side effects) when used as augmentation [5,12,56]. Additional data indicate that the stimulant class of medications, which induce release and block reuptake of dopamine and norepinephrine, augment and hasten antidepressant response when combined with TCAs [10,18,52], MAOIs [13,14], and SSRIs/SRNIs [27, 49]. Finally, dopamine agonists themselves (bromocriptine, pergolide) have shown efficacy as augmenting agents with antidepressants in open label studies [20,21 cited in 44].…”

Section: The Triple-action Hypothesismentioning

confidence: 99%

Triple Reuptake Inhibitors: The Next Generation of Antidepressants

Marks¹,

Pae²,

Patkar³

2008

View full text Add to dashboard Cite

Depression has been associated with impaired neurotransmission of serotonergic, norepinephrinergic, and dopaminergic pathways, although most pharmacologic treatment strategies for depression enhance only serotonin and norepinephrine neurotransmission. Current drug development efforts are aimed at a new class of antidepressants which inhibit the reuptake of all three neurotransmitters in the hope of creating medications with broader efficacy and/or quicker onset of action. The current review explores limitations of presently available antidepressants and the history and premise behind the movement to devise triple reuptake inhibitors. The evidence for and against the claim that broader spectrum agents are more efficacious is discussed. Examples of triple reuptake inhibitors in development are compared, and preclinical and clinical research with these agents to date is described.

show abstract

“…The combination of methylphenidate with, for instance, fluoxetine led to significant therapeutic improvement (Badet et al, 1998;Masand et al, 1998;Myronuk et al, 1996;Findling, 1996). Theoretically, as previously discussed, this new combination of medication could be neurotoxic to DA and/or 5-HT neurons.…”

Section: Introductionmentioning

confidence: 99%